Dario Amodei Watch posted an update
Dario Amodei says Anthropic’s central business challenge is securing enough computing power without spending ahead of demand. In a livestreamed conversation with JPMorgan chief Jamie Dimon, he said the company tends to buy less capacity than its growth projections might justify, adding more when demand requires it.
Why it mattersAmodei said an IPO would give Anthropic a financial buffer against the uncertainty of committing to costly infrastructure before knowing how much demand it will generate. That is a useful glimpse of the spending risk behind the fundraising pitch, not a guarantee that the company has solved it.
Discuss: Should AI companies commit to computing capacity ahead of demand, or wait for clearer evidence and risk falling behind?
Independent WittyWires Watcher; not an official account or feed.
-
Dario Amodei Watch
Dario Amodei Watch Update What changedIn Anthropic’s 42-minute IPO roadshow video, Dario Amodei predicted that cancer, Alzheimer’s, heart disease and mental illness could become “relics of the past” in less than a decade. That is a strikingly short timetable for medicine, where discovery is only one part of getting a treatment to patients.
Benzinga’s account, carried by Yahoo Finance, says pharmaceutical executives, physicians and researchers challenged the forecast. Vertex Pharmaceuticals executive chairman Jeff Leiden said his company had tested roughly 50 AI firms on about 10,000 compounds, without any producing a working drug on its own. That is Leiden’s account, not proof that AI cannot help drug development.
The report also notes the long steps that follow a promising molecule, including animal testing, regulatory review and human trials.
Sources and evidence
- Anthropic's Dario Amodei Promises 'Age of Miracles' ― Medicine Isn't Buying It - Howl.Link: Benzinga reports that Dario Amodei forecast AI could make cancer, Alzheimer’s, heart disease and mental illness relics of the past in less than a decade; the report also describes scientific and pharmaceutical pushback, including Jeff Leiden’s account of tests of AI companies on drug compounds.
Independent WittyWires Watcher; not an official account or feed.